Harvard Historical Balance Sheet

HBIO Stock

USD 1.93 0.01 0.52%

Trend analysis of Harvard Bioscience balance sheet accounts such as Net Debt of 46.5 M or Cash of 3.7 M provides information on Harvard Bioscience's total assets, liabilities, and equity, which is the actual value of Harvard Bioscience to its prevalent stockholders. By breaking down trends over time using Harvard Bioscience balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Harvard Bioscience latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Harvard Bioscience is a good buy for the upcoming year.

Harvard Bioscience Inventory

19.32 Million

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harvard Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.

About Harvard Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Harvard Bioscience at a specified time, usually calculated after every quarter, six months, or one year. Harvard Bioscience Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Harvard Bioscience and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Harvard currently owns. An asset can also be divided into two categories, current and non-current.

Harvard Bioscience Balance Sheet Chart

At this time, Harvard Bioscience's Short Term Debt is very stable compared to the past year. As of the 18th of January 2025, Intangible Assets is likely to grow to about 21.5 M, while Total Assets are likely to drop about 124.6 M.

Total Assets Total Stockholder Equity Net Debt Other Assets Cash And Short Term Investments

Add Fundamental

Total Assets

Total assets refers to the total amount of Harvard Bioscience assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Harvard Bioscience books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Harvard Bioscience balance sheet. This account contains Harvard Bioscience investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Harvard Bioscience fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Most accounts from Harvard Bioscience's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Harvard Bioscience current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harvard Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.At this time, Harvard Bioscience's Short Term Debt is very stable compared to the past year. As of the 18th of January 2025, Intangible Assets is likely to grow to about 21.5 M, while Total Assets are likely to drop about 124.6 M.

	2022	2023	2024	2025 (projected)
Total Stockholder Equity	72.2M	73.1M	84.0M	82.7M
Total Assets	145.4M	137.4M	158.0M	124.6M

Total Stockholder Equity Total Assets

Harvard Bioscience balance sheet Correlations

	Total Assets	Total Stockholder Equity	Net Debt	Cash	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Retained Earnings	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Inventory	Other Current Assets	Property Plant And Equipment Gross	Short Term Debt	Intangible Assets
Total Assets		0.79	0.58	0.24	0.04	0.24	0.88	0.91	0.82	0.9	0.69	0.25	0.69	0.35	-0.74	0.59	0.97	0.41	0.8	0.9	0.78	0.86	0.0	0.32	0.17	0.69
Total Stockholder Equity	0.79		0.04	0.61	0.23	0.61	0.64	0.76	0.3	0.95	0.18	-0.13	0.22	0.3	-0.42	0.49	0.63	0.16	0.84	0.72	0.24	0.6	0.16	0.07	0.43	0.42
Net Debt	0.58	0.04		-0.53	-0.31	-0.53	0.62	0.52	0.87	0.27	0.96	0.73	0.82	0.5	-0.77	0.38	0.72	0.43	0.26	0.57	0.85	0.66	-0.17	0.68	-0.17	0.5
Cash	0.24	0.61	-0.53		0.48	1.0	-0.06	0.07	-0.19	0.48	-0.3	-0.59	-0.35	-0.25	0.32	-0.11	0.08	-0.12	0.24	0.0	-0.16	-0.15	0.03	-0.44	0.43	0.18
Other Assets	0.04	0.23	-0.31	0.48		0.48	0.02	0.0	-0.16	0.18	-0.19	-0.19	-0.1	-0.17	0.17	-0.46	-0.04	0.23	-0.11	-0.03	-0.18	-0.06	0.04	-0.11	0.29	-0.33
Cash And Short Term Investments	0.24	0.61	-0.53	1.0	0.48		-0.06	0.07	-0.19	0.48	-0.3	-0.59	-0.35	-0.25	0.32	-0.11	0.08	-0.12	0.24	0.0	-0.16	-0.15	0.03	-0.44	0.43	0.18
Common Stock Shares Outstanding	0.88	0.64	0.62	-0.06	0.02	-0.06		0.98	0.76	0.78	0.63	0.47	0.83	0.52	-0.89	0.64	0.85	0.37	0.71	0.99	0.65	0.96	0.04	0.55	0.06	0.35
Other Stockholder Equity	0.91	0.76	0.52	0.07	0.0	0.07	0.98		0.7	0.86	0.55	0.36	0.72	0.49	-0.86	0.69	0.85	0.3	0.81	1.0	0.6	0.94	0.07	0.45	0.1	0.41
Total Liab	0.82	0.3	0.87	-0.19	-0.16	-0.19	0.76	0.7		0.51	0.9	0.51	0.87	0.27	-0.76	0.46	0.92	0.5	0.47	0.72	0.98	0.79	-0.16	0.44	-0.13	0.68
Total Current Assets	0.9	0.95	0.27	0.48	0.18	0.48	0.78	0.86	0.51		0.4	0.04	0.43	0.34	-0.61	0.54	0.76	0.17	0.85	0.83	0.45	0.74	0.01	0.19	0.35	0.5
Short Long Term Debt Total	0.69	0.18	0.96	-0.3	-0.19	-0.3	0.63	0.55	0.9	0.4		0.64	0.8	0.47	-0.73	0.33	0.8	0.44	0.31	0.58	0.9	0.64	-0.21	0.63	-0.06	0.6
Other Current Liab	0.25	-0.13	0.73	-0.59	-0.19	-0.59	0.47	0.36	0.51	0.04	0.64		0.76	0.64	-0.66	0.31	0.36	0.35	0.14	0.43	0.41	0.44	0.05	0.64	-0.5	0.02
Total Current Liabilities	0.69	0.22	0.82	-0.35	-0.1	-0.35	0.83	0.72	0.87	0.43	0.8	0.76		0.53	-0.8	0.49	0.78	0.53	0.41	0.76	0.77	0.81	-0.05	0.62	-0.18	0.31
Property Plant And Equipment Net	0.35	0.3	0.5	-0.25	-0.17	-0.25	0.52	0.49	0.27	0.34	0.47	0.64	0.53		-0.55	0.42	0.34	0.05	0.28	0.52	0.15	0.44	0.03	0.75	0.14	-0.03
Retained Earnings	-0.74	-0.42	-0.77	0.32	0.17	0.32	-0.89	-0.86	-0.76	-0.61	-0.73	-0.66	-0.8	-0.55		-0.62	-0.75	-0.32	-0.6	-0.88	-0.67	-0.87	0.02	-0.65	0.13	-0.36
Accounts Payable	0.59	0.49	0.38	-0.11	-0.46	-0.11	0.64	0.69	0.46	0.54	0.33	0.31	0.49	0.42	-0.62		0.56	0.17	0.73	0.71	0.38	0.71	0.15	0.25	-0.23	0.42
Non Current Assets Total	0.97	0.63	0.72	0.08	-0.04	0.08	0.85	0.85	0.92	0.76	0.8	0.36	0.78	0.34	-0.75	0.56		0.51	0.7	0.85	0.89	0.85	-0.01	0.38	0.06	0.74
Non Currrent Assets Other	0.41	0.16	0.43	-0.12	0.23	-0.12	0.37	0.3	0.5	0.17	0.44	0.35	0.53	0.05	-0.32	0.17	0.51		0.23	0.31	0.46	0.41	0.52	0.26	-0.1	0.24
Net Receivables	0.8	0.84	0.26	0.24	-0.11	0.24	0.71	0.81	0.47	0.85	0.31	0.14	0.41	0.28	-0.6	0.73	0.7	0.23		0.81	0.4	0.75	0.23	0.0	0.0	0.58
Common Stock Total Equity	0.9	0.72	0.57	0.0	-0.03	0.0	0.99	1.0	0.72	0.83	0.58	0.43	0.76	0.52	-0.88	0.71	0.85	0.31	0.81		0.62	0.95	0.07	0.48	0.05	0.41
Non Current Liabilities Total	0.78	0.24	0.85	-0.16	-0.18	-0.16	0.65	0.6	0.98	0.45	0.9	0.41	0.77	0.15	-0.67	0.38	0.89	0.46	0.4	0.62		0.7	-0.2	0.35	-0.12	0.76
Inventory	0.86	0.6	0.66	-0.15	-0.06	-0.15	0.96	0.94	0.79	0.74	0.64	0.44	0.81	0.44	-0.87	0.71	0.85	0.41	0.75	0.95	0.7		0.04	0.45	0.0	0.43
Other Current Assets	0.0	0.16	-0.17	0.03	0.04	0.03	0.04	0.07	-0.16	0.01	-0.21	0.05	-0.05	0.03	0.02	0.15	-0.01	0.52	0.23	0.07	-0.2	0.04		-0.12	-0.16	-0.09
Property Plant And Equipment Gross	0.32	0.07	0.68	-0.44	-0.11	-0.44	0.55	0.45	0.44	0.19	0.63	0.64	0.62	0.75	-0.65	0.25	0.38	0.26	0.0	0.48	0.35	0.45	-0.12		0.19	-0.1
Short Term Debt	0.17	0.43	-0.17	0.43	0.29	0.43	0.06	0.1	-0.13	0.35	-0.06	-0.5	-0.18	0.14	0.13	-0.23	0.06	-0.1	0.0	0.05	-0.12	0.0	-0.16	0.19		-0.07
Intangible Assets	0.69	0.42	0.5	0.18	-0.33	0.18	0.35	0.41	0.68	0.5	0.6	0.02	0.31	-0.03	-0.36	0.42	0.74	0.24	0.58	0.41	0.76	0.43	-0.09	-0.1	-0.07

Click cells to compare fundamentals

Harvard Bioscience Account Relationship Matchups

Harvard Bioscience balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	156.3M	162.3M	145.4M	137.4M	158.0M	124.6M
Total Stockholder Equity	76.7M	83.4M	72.2M	73.1M	84.0M	82.7M
Net Debt	39.7M	40.5M	42.3M	38.5M	44.3M	46.5M
Cash	8.3M	7.8M	4.5M	4.3M	3.9M	3.7M
Other Assets	2.3M	8.9M	12.3M	7.8M	8.9M	5.2M
Cash And Short Term Investments	8.3M	7.8M	4.5M	4.3M	3.9M	3.7M
Common Stock Shares Outstanding	38.6M	40.3M	41.4M	42.4M	48.8M	33.1M
Liabilities And Stockholders Equity	156.3M	162.3M	145.4M	137.4M	158.0M	124.6M
Other Stockholder Equity	221.7M	225.7M	229.0M	232.4M	267.3M	193.5M
Total Liab	79.6M	78.9M	73.1M	64.3M	73.9M	41.9M
Total Current Assets	51.7M	61.6M	51.1M	49.0M	56.4M	53.5M
Short Long Term Debt Total	48.0M	48.3M	46.8M	42.8M	49.2M	51.6M
Other Current Liab	7.2M	10.5M	7.5M	13.7M	15.8M	16.6M
Total Current Liabilities	21.1M	25.3M	23.2M	26.5M	30.5M	17.5M
Property Plant And Equipment Net	4.0M	3.4M	3.4M	8.8M	10.1M	10.6M
Retained Earnings	(132.4M)	(132.7M)	(142.2M)	(145.6M)	(131.0M)	(137.6M)
Accounts Payable	6.0M	4.9M	6.4M	5.6M	6.4M	5.7M
Non Current Assets Total	104.6M	100.8M	94.2M	88.3M	101.6M	73.6M
Non Currrent Assets Other	8.9M	12.3M	13.6M	6.5M	7.4M	4.1M
Net Receivables	17.8M	21.8M	16.7M	16.1M	18.5M	18.5M
Common Stock Total Equity	438K	444K	452K	454K	522.1K	407.4K
Non Current Liabilities Total	58.5M	53.6M	49.9M	37.8M	43.4M	25.8M
Inventory	22.3M	27.6M	26.4M	24.7M	28.4M	19.3M
Other Current Assets	3.4M	4.3M	3.5M	3.9M	4.5M	6.2M
Property Plant And Equipment Gross	11.7M	3.4M	24.0M	23.1M	26.6M	27.9M
Accumulated Other Comprehensive Income	(13.1M)	(10.0M)	(15.1M)	(14.2M)	(12.8M)	(12.1M)
Short Term Debt	3.8M	5.4M	5.9M	7.3M	8.4M	8.8M
Intangible Assets	33.2M	27.4M	21.0M	16.0M	14.4M	21.5M
Common Stock	444K	452K	454K	434K	499.1K	410.2K
Long Term Debt	46.3M	45.1M	43.0M	30.7M	35.3M	20.7M
Good Will	58.6M	57.7M	56.3M	57.1M	65.6M	46.4M
Property Plant Equipment	4.8M	4.0M	3.4M	3.4M	3.0M	3.5M
Current Deferred Revenue	3.8M	4.3M	3.4M	7.7M	8.9M	9.3M
Other Liab	2.1M	12.2M	8.5M	1.6M	1.8M	1.7M
Net Tangible Assets	24.3M	(15.1M)	83.4M	72.2M	65.0M	68.2M
Retained Earnings Total Equity	(124.6M)	(132.4M)	(132.7M)	(142.2M)	(128.0M)	(134.4M)
Capital Surpluse	229.2M	232.4M	225.7M	229.0M	263.4M	239.3M
Deferred Long Term Liab	2.3M	2.0M	1.9M	590K	678.5K	644.6K

When determining whether Harvard Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Harvard Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Harvard Bioscience Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Harvard Bioscience Stock:

How To Invest In Harvard

Details

Is Harvard Stock a good investment?

Details

What is Harvard Bioscience's Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.

You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harvard Bioscience. If investors know Harvard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harvard Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.80)

Earnings Share

(0.33)

Revenue Per Share

2.258

Quarterly Revenue Growth

(0.13)

Return On Assets

(0.02)

The market value of Harvard Bioscience is measured differently than its book value, which is the value of Harvard that is recorded on the company's balance sheet. Investors also form their own opinion of Harvard Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Harvard Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harvard Bioscience's market value can be influenced by many factors that don't directly affect Harvard Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Harvard Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harvard Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harvard Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Harvard Historical Balance Sheet

Harvard Bioscience Inventory

19.32 Million

About Harvard Balance Sheet Analysis

Harvard Bioscience Balance Sheet Chart

Total Assets

Total Stockholder Equity

Net Debt

Cash And Short Term Investments

Harvard Bioscience balance sheet Correlations

Harvard Bioscience Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Harvard Bioscience balance sheet Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Common Stock Total Equity	+ 1.0	Other Stockholder Equity
Common Stock Total Equity	+ 0.99	Common Stock Shares Outstanding
Other Stockholder Equity	+ 0.98	Common Stock Shares Outstanding
Non Current Liabilities Total	+ 0.98	Total Liab
Non Current Assets Total	+ 0.97	Total Assets

Retained Earnings	- 0.89	Common Stock Shares Outstanding
Common Stock Total Equity	- 0.88	Retained Earnings
Inventory	- 0.87	Retained Earnings
Retained Earnings	- 0.86	Other Stockholder Equity
Retained Earnings	- 0.8	Total Current Liabilities
Retained Earnings	- 0.77	Net Debt